MCQ Questions
🔍 Search
Menu

Biotechnology and Medical Technology Practice — MCQs with Answers (Set 3)

Practise 25 questions on Biotechnology and Medical Technology.

0 / 25 correct · click an option to check it

Q1. In which organism was RNA interference first characterised in detail, work that won a Nobel Prize in 2006?

Show answer and explanation

Answer: A

RNAi was first characterised in detail in the roundworm C. elegans, work that won Andrew Fire and Craig Mello the 2006 Nobel Prize.

Q2. Since when has a Hepatitis B vaccine existed?

Show answer and explanation

Answer: A

A Hepatitis B vaccine has existed since the early 1980s and is now part of routine childhood immunisation in most countries.

Q3. What can now cure most Hepatitis C infections, even without a vaccine?

Show answer and explanation

Answer: A

No vaccine exists for Hepatitis C, but direct-acting antiviral drugs can now cure most infections.

Q4. Which kind of vaccine is Covishield?

Show answer and explanation

Answer: D

The answer is a viral vector vaccine. It uses a replication-deficient chimpanzee adenovirus that carries the spike gene. It is not an mRNA vaccine. Memory hook: Covishield carries.

Q5. Which kind of vaccine is Covaxin?

Show answer and explanation

Answer: A

The answer is an inactivated whole-virus vaccine. One dose has 6 micrograms of whole-virion inactivated SARS-CoV-2 antigen. Memory hook: Covaxin kills.

Q6. After Cas9 makes a double-strand break, which repair route is the dominant one and is error-prone?

Show answer and explanation

Answer: B

NHEJ is the dominant route. It joins the ends without a template, so small insertions or deletions can appear. HDR needs a template and repairs precisely.

Q7. Why can a marker test shorten the time needed to breed a new variety?

Show answer and explanation

Answer: D

DNA can be taken from very young plants. The marker test can then be done long before the plant shows the trait. This can save months or even years. The eLibrary adds that marker-assisted selection is not always advantageous.

Q8. Amendment List 09 to the Indian Pharmacopoeia 2022 made testing mandatory for which toxic contaminants in all oral liquid medicines?

Show answer and explanation

Answer: C

The correct answer is Ethylene glycol and diethylene glycol. PIB (24 June 2026) says the amendment took effect on 10 October 2025. It makes testing for EG and DEG mandatory in all oral liquid formulations.

The other pairs are not named in the amendment. EG and DEG can enter through poor excipients such as glycerin or sorbitol.

Memory hook: EG and DEG in every oral liquid.

Q9. Which mode of testing was poorly understood before the IIT Patna rheometer?

Show answer and explanation

Answer: B

The answer is compression plus shear. Compression means squeezing. Shear means sliding layers. Existing methods gave only limited information. Memory hook: squeeze plus slide.

Q10. What is m102.4, the drug brought to Kerala for the 2018 Nipah outbreak?

Show answer and explanation

Answer: B

The answer is a human monoclonal antibody against Nipah virus. It is an antibody, not a vaccine. It came from the University of Queensland in Australia. Memory hook: Nipah, Kerala, m102.4.

Q11. BioE3 is implemented jointly by which two bodies?

Show answer and explanation

Answer: B

The correct answer is DBT and BIRAC. DBT is the Department of Biotechnology. BIRAC is its public sector enterprise. Memory hook: the department and its own council.

Q12. Under the Drugs (Prices Control) Order, 2013, which list decides the medicines placed in Schedule I?

Show answer and explanation

Answer: C

DPCO 2013 links Schedule I to the National List of Essential Medicines (NLEM). Only scheduled drugs get a ceiling price.

Q13. India’s first indigenous CRISPR-based gene therapy for sickle cell disease, BIRSA 101, was developed at which institute?

Show answer and explanation

Answer: B

PIB says BIRSA 101 was developed at CSIR-IGIB. The technology was then transferred to the Serum Institute of India. The name honours Birsa Munda.

Q14. Consider the following statements about BIRSA 101. 1. It was launched on 19 November 2025 as India’s first indigenous CRISPR-based gene therapy for sickle cell disease. 2. CSIR-IGIB and Serum Institute of India signed a technology transfer agreement for it. 3. IGIB says Phase I clinical trials are expected to begin in 2027. 4. It has already received CDSCO approval for patient use. How many of the statements given above are correct?

Show answer and explanation

Answer: C

Statements 1, 2 and 3 are correct. Statement 4 is wrong. No completed human trial or CDSCO approval has been found up to 1 November 2026. BIRSA 101 is an ex vivo therapy still before trials.

Q17. In gene therapy, what is a vector?

Show answer and explanation

Answer: B

Q18. Consider the following statements about Luxturna. 1. It is an adeno-associated virus vector-based gene therapy. 2. It is for subretinal injection. 3. It is approved to treat sickle cell disease. Which statements are correct?

Show answer and explanation

Answer: B

Q19. Which therapy became, in 2023, the first CRISPR gene-editing treatment to win regulatory approval, for sickle cell disease?

Show answer and explanation

Answer: C

Q24. The National Cancer Institute lists genomic, epigenomic and proteomic data among the output of the Cancer Genome Atlas (TCGA). Which other kind of data does it list?

Show answer and explanation

Answer: C

Beyond the answer

    Share your thoughts

    ✨Ask doubt
    ✨ Ask a Question AI×

    MCQ Question is an independent study site, not affiliated with any government body or exam authority. Official sources: UPSC upsc.gov.in · SSC ssc.gov.in · NCERT ncert.nic.in · PIB pib.gov.in

    WhatsApp support: +91 9319788829